icon-    folder.gif   Conference Reports for NATAP  
 
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
 
 
 
ANRS 146 - GeSIDA 7211 OPTIMAL Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts > 200 cells/ mm3
 
 
  Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
 
Yves Levy, Jean-Daniel Lelievre, Lambert Assoumou, Esther Aznar, Federico Pulido, Giuseppe Tambussi, Manuel Crespo, Agnes Meybeck, Jean-Michel Molina, Fanny Cardon, Constance Delaugerre, Remi Lancar, Lydie Beniguel, Dominique Costagliola and the OPTIMAL trial team

IAS1

IAS2

IAS3

IAS4

IAS5

IAS6